These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 20861820)

  • 1. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
    Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
    Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for metabolic bone disease in children with chronic kidney disease.
    Hahn D; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
    Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
    J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
    Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ; González EA
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are new vitamin D analogues in renal bone disease superior to calcitriol?
    Salusky IB
    Pediatr Nephrol; 2005 Mar; 20(3):393-8. PubMed ID: 15690188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of treatment of renal osteodystrophy on bone histology.
    Malluche HH; Mawad H; Monier-Faugere MC
    Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S157-63. PubMed ID: 18988701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
    Thadhani RI; Rosen S; Ofsthun NJ; Usvyat LA; Dalrymple LS; Maddux FW; Hymes JL
    Clin J Am Soc Nephrol; 2020 Mar; 15(3):384-391. PubMed ID: 32111702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.
    Kalantar-Zadeh K; Shah A; Duong U; Hechter RC; Dukkipati R; Kovesdy CP
    Kidney Int Suppl; 2010 Aug; (117):S10-21. PubMed ID: 20671739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.
    Coburn JW; Maung HM; Elangovan L; Germain MJ; Lindberg JS; Sprague SM; Williams ME; Bishop CW
    Am J Kidney Dis; 2004 May; 43(5):877-90. PubMed ID: 15112179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
    Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
    Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sevelamer hydrochloride and K/DOQI guidelines].
    Yumita S
    Clin Calcium; 2005 Sep; 15 Suppl 1():180-4. PubMed ID: 16279022
    [No Abstract]   [Full Text] [Related]  

  • 15. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F; Yudd M
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
    Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
    Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.
    Covic A; Passlick-Deetjen J; Kroczak M; Büschges-Seraphin B; Ghenu A; Ponce P; Marzell B; de Francisco AL
    Nephrol Dial Transplant; 2013 Sep; 28(9):2383-92. PubMed ID: 23787550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H; Koiwa F; Shishido K; Kinugasa E
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
    Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.